Despite the fact that adaptive biotechnologies corporation (nasdaq:adpt) stock rose 3.9% last week, insiders who sold us$229k worth of stock in the previous 12 months are likely to be better off. Adaptive biotechnologies has been rated by cowen , and william blair in the past 90 days.
Its clinical diagnostic product, clonoseq, is test authorized by the fda for the detection and monitoring of minimal residual.
Adaptive biotechnologies stock analysis. Quote stock analysis news price vs fair value sustainability trailing returns. Analyst estimates, including adpt earnings per share estimates and analyst recommendations. This compares to loss of $0.27 per share a year ago.
Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading. Adaptive biotechnologies corporation (adpt) saw an uptrend of 4.90% in the recent trading with $39.82 being its most recent. The stock has a consensus analyst rating of buy. a buy rating indicates that analysts believe adpt will outperform the market and that investors should add to their positions of adaptive biotechnologies.
And make sure their analysis is clear and in no way misleading or deceptive Investorsobserver gives adaptive biotechnologies corp (adpt) an overall rank of 37, which is below average. Their forecasts range from $52.00 to $74.00.
See our latest analysis for adaptive biotechnologies. Adaptive biotechnologies corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares.
Investors in adaptive biotechnologies corporation (nasdaq:adpt) have tasted that bitter downside in the last year, as the share price. Here's why adaptive biotechnologies rose 31.9% in. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip.
Adaptive biotechnologies currently has 2 hold ratings and 3 buy ratings from wall street analysts. Adpt stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. For the last reported quarter, it was expected that adaptive biotechnologies would post a loss of $0.43 per share when it actually produced a.
This suggests a possible upside of 127.6% from the stock's current price. Adaptive biotechnologies corp has a market cap of $4753661130. Find the latest adaptive biotechnologies corpor (adpt) stock quote, history, news and other vital information to help you with your stock trading and investing.
Adaptive biotechnologies (adpt) came out with a quarterly loss of $0.40 per share versus the zacks consensus estimate of a loss of $0.43. Adpt stock analysis overview what this means: 5 brokers have issued 1 year target prices for adaptive biotechnologies' shares.
Stock chart stock analysis is a method for investors and traders to make buying and selling decisions. Adpt | complete adaptive biotechnologies corp. Adaptive biotechnologies isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing.
On average, they expect adaptive biotechnologies' stock price to reach $60.33 in the next year. The company offers immunoseq research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; Analysts who follow adaptive biotechnologies corp on average expect it to climb 84.79% over the next twelve months.
Summary of all time highs, changes and price drops for adaptive biotechnologies; Those same analysts give the stock an average rating of strong buy. What analysts cover adaptive biotechnologies?
That average rating earns adpt an analyst ranking of 59, which means it ranks higher than 59 of stocks, based on data compiled by investorsobserver.
